---
figid: PMC4055851__109_2014_1161_Fig2_HTML
figlink: /pmc/articles/PMC4055851/figure/Fig2/
number: F2
caption: Mechanisms of resistance to anti-EGFR moAbs in mCRC. a Activating mutations
  of EGFR effectors, such as KRAS (by either point mutations or gene amplification),
  BRAF and PI3KCA, or PTEN loss of function, cause persistent activation of downstream
  signaling despite EGFR inhibition. b Aberrant activation (by either receptor gene
  amplification or high ligand levels) of alternative receptors, such as HER2 or MET
  (not shown), can bypass EGFR inhibition and mediate downstream pathway activation.
  c Additional genetic alterations within the target oncogene may abrogate drug binding.
  The EGFR S492R mutation inhibits cetuximab but not panitumumab binding, mediating
  acquired resistance to the former but not the latter in mCRC patients. d Other mechanisms
  of resistance may be “pathway independent,” such as altered angiogenesis (through
  increased secretion of VEGF or activation of VEGFR-1/2), dysregulation of EGFR recycling
  (with consequent increase of EGFR degradation), or tumor-stroma interactions (i.e.,
  through increased release of antiapoptotic growth factors and cytokines, such as
  HGF)
pmcid: PMC4055851
papertitle: 'Primary and acquired resistance to EGFR-targeted therapies in colorectal
  cancer: impact on future treatment strategies.'
reftext: Simonetta M. Leto, et al. J Mol Med (Berl). 2014;92(7):709-722.
pmc_ranked_result_index: '21384'
pathway_score: 0.9720239
filename: 109_2014_1161_Fig2_HTML.jpg
figtitle: Resistance to anti-EGFR moAbs in mCRC
year: '2014'
organisms: Homo sapiens
ndex: 4d0d6b41-dec5-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4055851__109_2014_1161_Fig2_HTML.html
  '@type': Dataset
  description: Mechanisms of resistance to anti-EGFR moAbs in mCRC. a Activating mutations
    of EGFR effectors, such as KRAS (by either point mutations or gene amplification),
    BRAF and PI3KCA, or PTEN loss of function, cause persistent activation of downstream
    signaling despite EGFR inhibition. b Aberrant activation (by either receptor gene
    amplification or high ligand levels) of alternative receptors, such as HER2 or
    MET (not shown), can bypass EGFR inhibition and mediate downstream pathway activation.
    c Additional genetic alterations within the target oncogene may abrogate drug
    binding. The EGFR S492R mutation inhibits cetuximab but not panitumumab binding,
    mediating acquired resistance to the former but not the latter in mCRC patients.
    d Other mechanisms of resistance may be “pathway independent,” such as altered
    angiogenesis (through increased secretion of VEGF or activation of VEGFR-1/2),
    dysregulation of EGFR recycling (with consequent increase of EGFR degradation),
    or tumor-stroma interactions (i.e., through increased release of antiapoptotic
    growth factors and cytokines, such as HGF)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK8
  - EGFR
  - BRAF
  - MAPK1
  - ERBB3
  - MAPK14
  - MAPK3
  - PIK3R5
  - AKT2
  - RAF1
  - MAPK12
  - ARAF
  - ERBB2
  - MTOR
  - NRAS
  - PIK3CA
  - MAPK11
  - VEGFC
  - PTEN
  - MAP2K1
  - AKT3
  - MAP2K2
  - HRAS
  - KRAS
  - VEGFB
  - PIK3R6
  - PIK3R4
  - MAPK9
  - PIK3R3
  - AKT1
  - MAPK13
  - VEGFA
  - PIK3CG
  - VEGFD
  - MAPK10
  - PGF
  - PIK3CB
  - PIK3CD
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: HER3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4055851__F2
redirect_from: /figures/PMC4055851__F2
figtype: Figure
---
